Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Aflibercept
DATE: 20/11/2024
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
